TLR2 and exocrine pancreatic carcinoma: The purpose of our study was to define the toxicity and efficacy of the toll-like receptor 2/6 agonist MALP-2 (Morr et al, 2002) in combination with gemcitabine for the treatment of unresectable pancreas carcinoma.